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T
  here  has  been  surprisingly  little  research 
in the public domain on the long-term safety and 
effectiveness  of  postmarket  drugs—drugs  that 














research.  These  centres  will  have  a  common  research 
agenda and strategic direction set by a DSEN steering 
committee. In addition, the DSEN will assist in coordin-


































spite  encouragements  to  conduct  postmarket  studies 
and to comply with postmarket commitments, there is 
evidence that drug manufacturers fail to do so and that 
drug  regulators  are  not  adequately  monitoring  post-







things,  will  give  the  government  authority  to  require 
drug manufacturers to conduct postmarket studies and 
to submit the resulting data for review.10,15,16    












drug  reactions  (and  possibly  in  the  future  to  conduct 
postmarket  studies),  the  DSEN  will  fund  “independ-

































First,  a  DSEN  good  governance  framework  (char-
acterized  by  the  existence  of  a  well-defined  operat-
ing structure, clear lines of operational accountability 
and  high  standards  for  integrity  and  openness)  must 







the  independence  of  researchers  are  essential  in  this 

























Our  support  for  CIHR  establishing  and  largely  ad-
ministering the DSEN is also conditional on the expecta-
tion that CIHR will be sufficiently funded and strongly 
independent  from  both  Health  Canada’s  Therapeutic 
Products Directorate and drug manufacturers since this 
is crucial for a public funding agency that has a man-
date  through  the  DSEN  to  promote  independent  drug 
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     Box 1: Key recommendations to ensure the independence 
     of the Drug Safety and Effectiveness Network (DSEN)
•  The DSEN must institute a good governance framework based 
on a sound approach to avoiding and mitigating conflict of 
interest. (See Box 2.)
•  The DSEN must have strong and enforceable conflict-of-interest 
rules for all those involved in DSEN-funded research and its 
reportage and knowledge translation.
•  The DSEN must have strong and enforceable measures to protect 
its independence and the independence of researchers from 
influence by Health Canada’s Therapeutic Products Directorate 
and drug manufacturers.
•  The DSEN steering committee must not include members who 
have financial interests in marketed products or have financial 
ties with those who do.
•  The DSEN must be structurally independent from CIHR activities 
relating to creating and maintaining CIHR–industry partnerships 
and collaborations.  Open Medicine 2010;4(2):e125
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surveillance  research.  The  commercialization  mandate 







In  the  spring  of  2009  we  presented  a  governance 
framework at a DSEN workshop on potential legal and 
ethical risks24 to address conflict-of-interest issues. We 











  Box 2:  Elaboration of the ￿  ve principles for good governance of the Drug and Safety E￿  ectiveness Network (DSEN)
  1.  Transparency and openness 
       Public disclosure of vital network information such as:
•  standards for evaluating the network
•  governance arrangements
•  standards for selecting researchers, staﬀ   and centres of excellence
•  standards for evaluating researchers
•  standards for obtaining and dealing with stakeholders input
•  standards regarding sources and use of data
•  standard procedure for registration of clinical trials and results reporting
•  confl  ict-of-interest (COI) disclosures by everyone in the network (e.g., oﬃ   cials, researchers)
•  procedures for dealing with COI
  2.  Accountability 
       Being subject to clear rules of behaviour and being publicly answerable, such as
•  existence of clear governance arrangements; partnerships; agreements and policies for 
protecting academic values and the integrity of the network (including its data)
•  eﬃ   ciency and enforceability of policies and procedures (especially concerning COI, privacy and confi  dentiality)
•  DSEN COI committee: clear authority over COI matters for all DSEN research; uniformity of 
COI standards for addressing COI across the network for DSEN-related research
•  external verifi  cation and answerability: registering trials; publishing results independently and within a specifi  c period
•  accountability to CIHR
•  accountability of centres of excellence to central DSEN administration  
  3.  Independence  
       Autonomy from stakeholders, such as
•  autonomy from commercial infl  uences
•  arm’s length from regulatory authorities in areas such as governance; budget; setting policies 
and enforcing them (especially COI and confi  dentiality); research priorities, selecting researchers; 
evaluating network oﬃ   cials and researchers; interpreting data and reporting
•  elements: budgetary “independence” (medium- to long-term security); structural and human resources independence
•  clear rules about representation and confl  icts of interest of public stakeholders
•  commitment to public interest promotion with protection against inappropriate capture by special interest groups
  4.  Commitment to scientifi  c integrity 
        Dedication to scientifi  c honesty, such as
•  preservation of scientifi  c integrity and academic freedom, including selecting 
researchers who will have as few confl  icts of interest as possible
•  access to full data and appropriate control over it
•  absence of legal constraints associated with access to data and use of data
•  support for the conduct of research that is consistent with academic values: unbiased, truthful and rigorous   
  5.  Freedom of action: de facto and de jure
•  ability to act independently from commercial infl  uences and being at arm’s length 
from regulatory authorities, in the best interests of the public
•  absence of constraints associated with potential liability for good faith actions (e.g., insurance, 
commitment of stakeholders to respecting independence of researchers)
•  absence from legal constraints fl  owing from contracts or arrangements that aﬀ  ect the ability (or the perception of ability) 
to meet commitments to the core principles (transparency and openness, accountability, independence, commitment to 
















DSEN  steering  committee  should  be  carefully  chosen 
to  avoid  situations  of  conflict  of  interest.  Members  of 
the steering committee should not have financial inter-
ests  in  marketed  products  or  have  financial  ties  with 
those  who  do.  Although  having  the  DSEN  operating 
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  Box 3: Principles for avoiding and mitigating con   ict of interest (COI) among researchers and researchers’ 
                   host institutions involved with the Drug Safety and E￿  ectiveness Network (DSEN)
  1.  Transparency and openness 
•  full disclosure of potential, actual or perceived COI of researcher (and his or her family)
•  balance between access to information on COI and the privacy interests of individuals
•  creation of transparent rules and processes and reliable oversight of COI
  2.  Accountability 
•  avoidance of COI situations if possible
•  adherence to network COI policies and procedure
•  enforcement of COI rules and sanctions
•  introduction of “presumption” that researchers cannot have COI, and clear rules 
of conduct for when exceptions are appropriate and needed
  3.  Independence  
•  monetary (actual, perceived or future) independence and academic independence from 
commercial infl  uences and remaining at arm’s length from regulatory authorities
•  procedures to deal with centre of excellence host institution COIs and their potential impact on researcher COI 
•  role of DSEN in strengthening researcher independence in situations of centre of excellence host institutional COI
•  protection of researchers against threat of legal procedures by pharmaceutical sponsors for DSEN-related research 
  4.  Scientifi  c integrity 
•  research that is consistent with academic values (e.g., remaining impartial and truthful, conducting rigorous 
evaluations with scientifi  c merit, adhering to protocols, publishing/disseminating fi  ndings)
•  education and support of DSEN researchers (e.g., education on COI issues and DSEN standards for dealing with 
them, support of independence of researchers, raising awareness of importance of structural independence) 
  5.  Freedom of action: de facto and de jure
•  ability to remain free to conduct research that has scientifi  c integrity and that is 
consistent with network responsibilities, policies and procedures













We  commend  the  CIHR  in  co-hosting,  with  Health 












operate  from  the  core  principles  of  transparency  and 
openness, accountability, independence, commitment to 
scientific integrity and freedom of action.
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